A Quick ASCO Update
Research - Initial data from the upcoming ASCO annual meeting (American Society of Clinical Oncology annual meeting) dropped last night when abstracts were released at 5:00 PM … Continue Reading
Read NowResearch
A Review of Our Latest Biotech Investing Ideas
Research - Even with Alexion Pharmaceuticals (ALXN) announcing Wednesday morning the acquisition of Synageva (GEVA) for a heady $8 billion, aggressive dip-buyers are still absent in the … Continue Reading
Premium: Read Now
Celladon’s Sweeping Impact on Biotech
Research - It’s happened– the first high-profile failure from the re-emerging cohort of publicly traded gene therapy developers. Celladon (CLDN) reported on Sunday that MYDICAR, the company’s … Continue Reading
Read Now
What Makes Affimed An Interesting – albeit Under-followed – Drug Developer
Research - Completing their IPO in September 2014 and raising $56 million, Affimed Therapeutics (AFMD) is a German clinical-stage biopharmaceutical company developing targeted cancer immunotherapies. Affimed’s product … Continue Reading
Read NowOncology Stocks to Watch (or Trade) into ASCO 2015
Research - The annual meeting of the American Society of Clinical Oncology is almost here. Here are a number of names to watch, and potentially trade, into the event.
Read Now
uniQure Dips on New Risk Disclosure
Research - It was just 5 days ago that Bristol-Myers Squibb (BMY) partnered with uniQure (QURE) on the discovery and development of novel gene therapies for cardiovascular … Continue Reading
Read Now
Why GBIM is Up 40% in Four Days – and What to Do About It
Research - Our suggestion in November was to be long GBIM from below $6.00 in anticipation of data this quarter for GS-4774. We're up 75%. Here's what to do next.
Premium: Read Now